



With Gratitude to Alan's Legacy

Respectfully prepared for Sophia Bell

On behalf of Children's Hospital of Philadelphia Foundation, CHOP Cancer Center, and our Cellular Immunotherapy Program, thank you and Alan's Legacy for your support and dedication to our research efforts. Your compassion and commitment to CHOP are deeply meaningful to our team. This year, *U.S. News & World Report* again ranked CHOP's pediatric cancer program among the top in the nation and it's because of donors such as Alan's Legacy that we are able to continue to innovate, find the right answers, and lead the way.

At CHOP, our goal is to bring the most effective treatments to the most patients as quickly as possible, and for ten years, your contributions have supported this vision. Thanks to the generosity of donors such as Alan's Legacy, CHOP continues to advance this work through our Immunotherapy Program. In this space, important advancements and milestones include:

- Leading clinical trials into the first form of CAR T-cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed and refractory pediatric acute lymphoblastic leukemia (ALL). The therapy is the first personalized cellular therapy for the treatment of cancer to receive FDA approval.
- The first to use investigational CAR T-cell therapy in a child with ALL, who remains cancer-free.
- The largest cohort of pediatric patients treated with CAR T cells targeting CD19 and the longest follow-up.
- Identified and applied a treatment to decrease the severity of potentially fatal toxic side effects of CAR T-cell therapy. This approach is now used worldwide for children and adults treated with CAR T-cells and other new immunotherapies.
- Continues to research the use of CAR T-cell therapy in the treatment of several other forms of pediatric cancer, with the hopes of expanding its use to fight other forms of leukemia and solid tumors